BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10691864)

  • 1. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm.
    Valkov NI; Gump JL; Engel R; Sullivan DM
    Br J Haematol; 2000 Feb; 108(2):331-45. PubMed ID: 10691864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
    Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
    Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
    Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
    Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting.
    Padget K; Pearson AD; Austin CA
    Leukemia; 2000 Nov; 14(11):1997-2005. PubMed ID: 11069037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
    Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
    Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
    Towatari M; Adachi K; Marunouchi T; Saito H
    Br J Haematol; 1998 Jun; 101(3):548-51. PubMed ID: 9633900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
    Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.
    Uesaka T; Shono T; Kuga D; Suzuki SO; Niiro H; Miyamoto K; Matsumoto K; Mizoguchi M; Ohta M; Iwaki T; Sasaki T
    J Neurooncol; 2007 Sep; 84(2):119-29. PubMed ID: 17361331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
    Hirota H; Gosky D; Berger NA; Chatterjee S
    Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
    Satterwhite DJ; White RL; Matsunami N; Neufeld KL
    Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
    Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
    Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
    Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
    Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
    Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
    J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.